Development of WF10, a novel macrophage-regulating agent. McGrath, M.S., Kahn, J.O. and Herndier, B.G. Current Opinion in Investigational Drugs 3 (3): 365-373, 2002.

Balanced macrophage activation hypothesis: A biological model for development of drugs targeted at macrophage functional states. McGrath, M.S. and Kodeljab, V. Pathobiology 67: 277-281, 1999.

Alteration of T-cell activation by WF10, a potential modulator of macrophage function. Kahn, J., Glidden, D., Brosz, M., Kuehne, F. and Herndier, B.
2nd Teupitzer Colloquium "Macrophages in anti-inflammation", September 1999, Teupitz, Germany.

WF10 interference with early and late in vitro activation of T-cell responses. Engleman, E., Benike, C. and McGrath, M.S.
2nd Teupitzer Colloquium "Macrophages in anti-inflammation", September 1999, Teupitz, Germany.

Effect of WF10 (TCDO) on antigen presentation. McGrath, M.S., Benike, C., Kuehne, F.-W. and Engleman, E.
Transplantation Proceedings 30: 4200-4204, 1998.

Inhibition of antigen presentation by WF10 (TCDO). Engleman, E., Benike, C., Kuehne, F. and McGrath, M.S.
American Association of Immunologists' Experimental Biology Conference, April 1998, San Francisco, USA.

To see publications for Transdermal Drug Delivery, click here.
To see publications for Technology, click here.